BioNexus Gene Lab Corp (BGLC) grants CEO 338,709 fully vested shares

Rhea-AI Filing Summary

Tan Lee Su-Leng reported acquisition or exercise transactions in this Form 4 filing.

BioNexus Gene Lab Corp reported that Chief Executive Officer and director Tan Lee Su-Leng, a more than 10% shareholder, received a fully vested stock award. The award consists of 338,709 common shares with no par value, granted on August 13, 2026 under the company’s 2025 Equity Incentive Plan.

The shares were granted for completed services, with no cash consideration, and were valued for plan purposes at $1.55 per share, based on the Nasdaq closing price on August 12, 2026. Following this grant, the reporting person directly holds 338,709 common shares.

Insider Trade Summary

Net Buyer: 338,709 shares

Net Buy 1 txn

Insider Tan Lee Su-Leng

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	338,709	--	--

Holdings After Transaction: Common Shares — 338,709 shares (Direct)

Footnotes (1)

1. F1. Represents a fully vested Other Stock-Based Award of 338,709 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

Key Figures

Shares granted: 338,709 shares Plan valuation price: $1.55 per share Shares owned after grant: 338,709 shares

3 metrics

Shares granted 338,709 shares Fully vested Other Stock-Based Award granted August 13, 2026

Plan valuation price $1.55 per share Nasdaq closing price on August 12, 2026 used for plan purposes

Shares owned after grant 338,709 shares Total common shares directly held following the reported transaction

Key Terms

Other Stock-Based Award, no par value, 2025 Equity Incentive Plan

3 terms

Other Stock-Based Award financial

"Represents a fully vested Other Stock-Based Award of 338,709 shares"

no par value financial

"shares of common stock, no par value, granted on August 13, 2026"

2025 Equity Incentive Plan financial

"granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan"

FAQ

What insider transaction did BioNexus Gene Lab Corp (BGLC) disclose?

BioNexus Gene Lab Corp disclosed that its CEO, Tan Lee Su-Leng, received a fully vested stock award of 338,709 common shares on August 13, 2026 for completed services, with no cash consideration involved.

How many BioNexus Gene Lab Corp (BGLC) shares were granted to the CEO?

The CEO of BioNexus Gene Lab Corp was granted 338,709 common shares. These shares are fully vested and were awarded as an Other Stock-Based Award under the 2025 Equity Incentive Plan for services already completed.

At what value was the BioNexus Gene Lab Corp (BGLC) stock award priced for plan purposes?

The stock award was valued for plan purposes at $1.55 per share, corresponding to the Nasdaq closing price of BioNexus Gene Lab Corp common stock on August 12, 2026, immediately before the grant date.

Did BioNexus Gene Lab Corp (BGLC) receive cash from this insider stock award?

No cash was received; the 338,709-share award to the CEO was granted for completed services and specifically stated to be for no cash consideration, reflecting a compensation grant rather than a cash transaction.

How many BioNexus Gene Lab Corp (BGLC) shares does the CEO hold after this grant?

After the grant, the CEO directly holds 338,709 common shares of BioNexus Gene Lab Corp. The filing reports this as the total number of shares owned following the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:21 PM Accepted by SEC EDGAR 08/14/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tan Lee Su-Leng

(Last) (First) (Middle)

A-28-7, MENARA UOA BANGSAR

NO.5 JALAN BANGSAR UTAMA 1

(Street)

KUALA LUMPUR 59000

(City) (State) (Zip)

MALAYSIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNexus Gene Lab Corp [ BGLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/13/2026		A		338,709	A	(1)	338,709	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a fully vested Other Stock-Based Award of 338,709 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

	/s/ Su-Leng Tan Lee	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)